Monopar Therapeutics’ (MNPR) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report report published on Thursday,Benzinga reports. They currently have a $100.00 price target on the stock.

Other equities analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Barclays set a $125.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a research report on Monday, October 13th. Oppenheimer set a $115.00 target price on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $107.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR opened at $60.38 on Thursday. Monopar Therapeutics has a one year low of $26.06 and a one year high of $105.00. The stock has a market capitalization of $403.34 million, a P/E ratio of -17.55 and a beta of 1.46. The firm’s 50 day simple moving average is $71.94 and its two-hundred day simple moving average is $65.62.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). As a group, equities analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In related news, CFO Quan Anh Vu bought 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was bought at an average cost of $69.95 per share, with a total value of $104,925.00. Following the completion of the purchase, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics during the third quarter valued at about $28,000. BNP Paribas Financial Markets boosted its stake in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Monopar Therapeutics during the 2nd quarter valued at approximately $34,000. AlphaQuest LLC grew its holdings in Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after buying an additional 569 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.